Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38
Canaccord Genuity 維持對Corcept Therapeutics的買入,將目標股價提高至38美元
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $37 to $38.
Canaccord Genuity分析師愛德華·納什維持Corcept Therapeutics(納斯達克股票代碼:CORT)的買入,並將目標股價從37美元上調至38美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。